drugset / Trial / NCT02395601
A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas
NaSingle-groupOpen-labelTreatment
Summary
First in human, open-label, sequential dose escalation and expansion study of CPI-1205 in patients with progressive B-cell lymphomas. CPI-1205 is a small molecule inhibitor of EZH2.
Timeline
- Start
- 2015-03
- Primary completion
- 2018-12
- Completion
- 2018-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CPI-1205 | Small molecule | — | — |